Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.

Br J Clin Pharmacol · 2022 · PMC9302693 · PMID 35029306

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an apparent trendno p-value reported

Neutropenia is the only grade ≥3 AE showing an apparent trend towards increasing from Q1 to Q4 in PFS.

also in 709 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.